Company Overview and News

1
Netflix's (NFLX) Q3 Earnings to Benefit From Content Strength

2018-10-11 zacks
Netflix Inc. (NFLX - Free Report) is set to report third-quarter 2018 results on Oct 16. Notably, the company’s earnings have beaten the Zacks Consensus Estimate in two of the trailing four quarters, delivering an average negative surprise of 0.39%. In the last reported quarter, the company’s earnings of 85 cents per share surpassed the Zacks Consensus Estimate by a nickel. The figure was much better than 15 cents reported in the year-ago quarter.
SJR.B AAPL SJR NFLX SJRWF SJR.A

 
Shaw Launches Affordable, Enterprise-Grade Networking Solution to Keep Businesses Connected

2018-10-01 globenewswire
CALGARY, Alberta, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. today announced the launch of a next-generation networking solution that gives businesses of all sizes the ability to share business data and critical applications between head offices and their branch locations at up to half the cost of traditional networking solutions.
SJR.B WIREX SJR SJRWF SJR.A

53
What Sector Reclassifications Mean

2018-09-30 blackrockblog
Investors might need to relearn some long-held assumptions following a major reshuffle of stock sector classifications.
FB SJR.B SJR NFLX SJRWF GOOG CPXGF SJR.A BABA AMZN GOOGL BIDU

3
Shaw Communications Gains From Growth of Wireless Business

2018-09-25 zacks
On Sep 25, we issued an updated research report on Shaw Communications Inc. (SJR - Free Report) . The company is a provider of broadband cable television services, Internet, digital phone, telecommunications services, Direct-to-Home (DTH) satellite services and satellite distribution services in the United States and Canada. Solid growth in the Wireless business, as well as improving customer base in the Wireline Video: Satellite business, is the key catalyst for Shaw Communications.
SJR.B VSH SJR SJRWF NTAP PAYC SJR.A

 
Telus: Long-Term Wealth Generating Stock

2018-09-19 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Sapient Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
SJR.B CMCSA SJR SJRWF TU SJR.A

11
6 Monthly Dividend Stocks to Buy

2018-09-14 investorplace - 1
Most dividend stocks pay their shareholders quarterly, but a few dividend yielding stocks offer monthly distributions.
SJR.B WBA LTC SJRWF OPRF SJR.A KMI PAA KMR STAG CVB APLE O SJR FDX MAR HLT PBA KMRFZ

 
Shaw Communications Inc. Fourth Quarter Fiscal 2018 Conference Call

2018-09-12 globenewswire
CALGARY, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (“Shaw”) will be releasing its consolidated results for the Fourth Quarter (ending August 31, 2018) the morning of Thursday, October 25, 2018.
SJR.B WIREX SJR SJRWF SJR.A

1
Shaw Provides Dividend Rate Notice for Cumulative Redeemable Floating Rate Class 2 Preferred Shares, Series B

2018-08-31 globenewswire - 1
CALGARY, Alberta, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (“Shaw”) announced today that it has given the registered shareholders of its Cumulative Redeemable Floating Rate Class 2 Preferred Shares, Series B (the “Series B Shares”) notice of dividend rates.
SJR.B WIREX SJR SJRWF SJR.A

 
SugarBud Craft Growers Corp. Provides Update Regarding Management Changes and Additions, Funding of Cannabis Operations, Insider Participation in Rights Offering, Investment in Inner Spirit Holdings Ltd. and Announces Option Grant

2018-08-10 globenewswire
CALGARY, Alberta, Aug. 09, 2018 (GLOBE NEWSWIRE) -- SugarBud Craft Growers Corp. (“SugarBud” or the “Company”) is pleased to announce that it has appointed Mr. Craig Kolochuk, SugarBud’s President, to the position of President and Chief Executive Officer, Mr. Sander Steer to the position of Vice President, Growing Operations, Infrastructure and Technology and Mr. Corey Scott to the position of Master Cultivator.
CJ SJR.B CRLFF SJR SJRWF SJR.A

 
PRESS DIGEST - Canada - Aug 8

2018-08-08 reuters
Aug 8 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
BCE RCIAF RCI SJR.B KML SJR SJRWF MAXR SJR.A

 
BCE: Investors Should Look Beyond Its Near-Term Weakness

2018-08-07 seekingalpha
Investors of BCE should look beyond its near-term weakness and look forward to the opportunities in the era of 5G.
RCIAF RCI SJR.B SJR BCE SJRWF QBCRF SJR.A

 
Bell subscriber base grows, but BCE Q2 misses estimates

2018-08-02 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BCE RCIAF RCI SJR.B BCEXF SJR SJRWF SJR.A

 
You Deserve More Data. You Deserve Freedom: Will Arnett Sends Canadians a Message in New Freedom Mobile Ad Campaign

2018-08-01 globenewswire
CALGARY, Alberta, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Freedom Mobile today unveiled a bold new advertising campaign that highlights the expensive pain points that consumers often experience with their wireless service and shows Canadians that they can get more value through Freedom Mobile.
SJR.B WIREX SJR SJRWF SJR.A

 
More Canadians Get Fairer Pricing With New Plans From Freedom Mobile

2018-07-19 globenewswire
CALGARY, Alberta, July 19, 2018 (GLOBE NEWSWIRE) -- New wireless service plans announced today by Shaw Communications’ Freedom Mobile give Canadians more affordability and greater transparency into the services they are paying for from their mobile provider.
SJR.B SJR WIREX SJRWF SJR.A

 
Rogers beats profit estimates as wireless adds more users - Channel NewsAsia

2018-07-19 channelnewsasia
Rogers Communications Inc topped analysts' estimates for quarterly profit on Thursday, as more subscribers signed up for the Canadian telecom company's wireless postpaid services.
BCE RCIAF RCI SJR.B SJR SJRWF TU SJR.A

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...